NCT00764972Unknown1 期
A Phase IB/II Trial of Combination of Vinorelbine With Sorafenib (BAY 43-9006) as First-Line Treatment in Patients With Metastatic Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Confirmed complete response (CR) or partial response (PR), defined according to RECIST criteria, persisting 4 weeks after the initial documentation.
研究概览
简要总结
This is a phase IB/II trial of sorafenib, a new tyrosine kinase inhibition of multiple genes that is active against renal cancer, plus vinorelbine, a chemotherapy agent active in breast cancer.
The investigators are combining these 2 drugs in order to determine if the investigators can increase the activity of vinorelbine in metastatic breast cancer patients.
Patients with measurable metastatic breast cancer without previous chemotherapy for metastatic disease are eligible for the protocol. They will be treated with 2 different dose levels of sorafenib in order to determine the most tolerable dose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 65 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Women affected by histologically proven metastatic breast cancer.
- •Tumor not susceptible to therapy with trastuzumab, defined as FISH negative for HER-2 amplification or immunohistochemistry 0-1+ for HER-2 expression.
- •Female, age ≥
- •Documented measurable disease by appropriate radiologic imaging according to RECIST criteria (see Appendix E). Lesions in previously irradiated areas are not considered measurable disease, unless progression has been documented post-radiation.
- •ECOG performance status 0-1 (see Appendix B)
- •Life expectancy > 6 months.
- •Adequate bone marrow function, as indicated by:
- •Hemoglobin ≥ 90 g/L
- •Neutrophils ≥ 1.5 x 109/L
- •Platelets ≥ 100 x 109/L
- •Adequate renal function, as indicated by serum creatinine ≤1.5 times the upper limit of normal and/or Creatinine Clearance calculated as >50% lower normal limit, or estimated as ≥ 50 ml/min (Appendix C).
- •Adequate liver function, as indicated by:
- •bilirubin ≤ 1.5 times upper normal limit;
- •AST and ALT ≤ 2 times upper normal limit.
- •Left ventricular ejection fraction (LVEF) ≥50% as measured by either multigated acquisition (MUGA) scan or echocardiogram (ECHO).
- •No therapy for breast cancer in the 4 weeks preceding the therapy start.
- •Women of childbearing potential must be using adequate contraception and have a negative pregnancy test at the time of enrollment.
- •Patient able to understand and give written informed consent.
排除标准
- •Patients with locally advanced breast cancer or stage IIIb only.
- •Presence of only non-measurable disease.
- •Previous (neo)adjuvant chemotherapy with vinorelbine.
- •Any previous anti-angiogenic therapy.
- •Any previous chemotherapy for metastatic breast cancer. Previous hormonal treatments or radiotherapy for metastatic disease are allowed.
- •Radiotherapy, chemotherapy or hormonal therapy for breast cancer in the last 4 weeks prior to starting the study treatment.
- •Major surgery within 4 weeks of first study treatment, or minor surgery (including placement of an access device) within 7 days of therapy start.
- •Presence of life-threatening disease or central nervous system localizations.
- •Evidence of HER-2 positive breast cancer, defined as FISH-positive for amplification or score 3+ by immunohistochemistry.
- •Any other possibly active primary tumor, except basal cell carcinoma of the skin, or carcinoma in situ of the cervix.
- •Clinically significant hepatic disease with respect to hepatitis B, hepatitis C, cirrhosis or other liver diseases.
- •Uncontrolled bacterial, viral or fungal infection.
- •Previous history of ischemic disease.
- •Patients with previous history of thrombo-embolic events, or with documented risk factors for thrombotic disease other than cancer.
- •History of gross hemorrhage within the past 6 months (e.g., hemoptysis or hematuria requiring medical intervention).
- •Uncontrolled hypertension.
- •Other serious medical conditions, such as uncontrolled cardiac disease, severe pulmonary disease, uncontrolled diabetes.
- •Patient exhibiting confusion or disorientation.
- •Any condition (medical, social, psychological, geographical) that would prevent adequate follow-up.
- •Patient is pregnant, or is breast-feeding, or is unwilling to use adequate contraception.
- •Failure to give informed consent.
研究组 & 干预措施
Sorafenib and Vinorelbine
Experimental
干预措施: Sorafenib and Vinorelbine (Drug)
结局指标
主要结局
Confirmed complete response (CR) or partial response (PR), defined according to RECIST criteria, persisting 4 weeks after the initial documentation.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
A Phase II Trial of Sorafenib (a tyrosine kinase inhibitor) given orally twice daily in renal cancer patients with vHL syndrome - Oral Sorafenib in renal cancer patients with vHL syndromevon Hippel Lindau syndrome (vHL) is a rare genetic disorder that causes a predisposition to develop multiple tumours, including renal, CNS and retinal tumours. vHL patients who have solid renal tumours (< or =2.4 cm) will require surgery to remove the renal tumours once they reach 2.5cm or greater. Disease-stabilising agents such as sorafenib could potentially delay or avoid the need for surgery.MedDRA version: 9.1Level: LLTClassification code 10047716Term: Von Hippel-Lindau diseaseEUCTR2007-002132-29-GBOxford Radcliffe Hospitals NHS Trust25
暂停
1 期
Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular TargetsAdvanced Solid TumorsNCT01226056Southern Europe New Drug Organization45
已完成
2 期
Sorafenib + mFOLFOX for Hepatocellular CarcinomaHepatocellular CancerNCT01775501Massachusetts General Hospital40
已完成
1 期
Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal CancerRecurrent Colon CancerRecurrent Rectal CancerStage III Colon CancerStage III Rectal CancerStage IV Colon CancerStage IV Rectal CancerNCT00134069National Cancer Institute (NCI)48
撤回
1 期
Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal MetastasisBreast CarcinomaMetastatic Malignant Neoplasm in the BrainMetastatic Malignant Neoplasm in the LeptomeningesNCT06137651Northwestern University